Phase 2 trials (Jastreboff et al., NEJM, 2023) have shown it to be highly effective for weight reduction in adults with obesity
Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities
R., Busby-Whitehead, J., Tsiao, C., Stewart, K
Each line generates about 20M pens per year, ~80M auto-injectors total
Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression
Here are some examples of GLP-1 agonists: Dulaglutide (marketed as Trulicity) Exenatide (marketed as Byetta and Bydureon) Liraglutide (marketed as Victoza) Lixisenatide (marketed as Adlyxin) Semaglutide (marketed as Ozempic and Rybelsus) Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis: The Glucagon-like Peptide-1 (GLP-1) Agonists Market size is estimated at USD 11.87 billion in 2023, and is expected to reach USD 12.55 billion by 2028, growing at a CAGR of 1.12% during the forecast period (2023-2028)